"Cell Line, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell line derived from cultured tumor cells.
| Descriptor ID |
D045744
|
| MeSH Number(s) |
A11.251.210.190 A11.251.860.180
|
| Concept/Terms |
Cell Line, Tumor- Cell Line, Tumor
- Cell Lines, Tumor
- Line, Tumor Cell
- Lines, Tumor Cell
- Tumor Cell Lines
- Tumor Cell Line
|
Below are MeSH descriptors whose meaning is more general than "Cell Line, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Cell Line, Tumor".
This graph shows the total number of publications written about "Cell Line, Tumor" by people in this website by year, and whether "Cell Line, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 17 | 17 |
| 2004 | 0 | 57 | 57 |
| 2005 | 0 | 63 | 63 |
| 2006 | 1 | 58 | 59 |
| 2007 | 0 | 69 | 69 |
| 2008 | 1 | 80 | 81 |
| 2009 | 2 | 109 | 111 |
| 2010 | 0 | 88 | 88 |
| 2011 | 1 | 118 | 119 |
| 2012 | 2 | 89 | 91 |
| 2013 | 2 | 116 | 118 |
| 2014 | 0 | 131 | 131 |
| 2015 | 0 | 138 | 138 |
| 2016 | 0 | 151 | 151 |
| 2017 | 0 | 120 | 120 |
| 2018 | 0 | 132 | 132 |
| 2019 | 1 | 130 | 131 |
| 2020 | 0 | 121 | 121 |
| 2021 | 0 | 117 | 117 |
| 2022 | 0 | 40 | 40 |
| 2023 | 0 | 56 | 56 |
| 2024 | 0 | 101 | 101 |
| 2025 | 0 | 126 | 126 |
| 2026 | 0 | 33 | 33 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
Identification of CAND1 as a DNA-dependent protein kinase-regulated coactivator of androgen receptor and the ARv7 splice variant. PLoS One. 2026; 21(5):e0349130.
-
Role of the ETV5/p38 Signaling Axis in Aggressive Thyroid Cancer Cells. Mol Cancer Ther. 2026 May 04; 25(5):844-859.
-
Alprazolam Reduces Inflammatory Cytokine Production in Pancreatic Cancer-Associated Fibroblasts. Cancer Res Commun. 2026 May 01; 6(5):1048-1060.
-
Imbalance Between CD44 and STAT3 Enhances Spheroid Viability and Impairs Pembrolizumab Response in Urothelial Cancer. Anticancer Res. 2026 May; 46(5):2445-2453.
-
Chemotherapy-induced activation of caspase-1 and IL-1a release by cancer cells remotely skews myelopoiesis to drive pro tumorigenic systemic neutrophil-dominant inflammation. Nat Commun. 2026 Apr 20; 17(1).
-
Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer. Clin Cancer Res. 2026 Apr 15; 32(8):1454-1461.
-
LRRC15-CAR T Cells for the Treatment of Osteosarcoma. Clin Cancer Res. 2026 Apr 15; 32(8):1557-1573.
-
Loss of ZNRF3/RNF43 unleashes EGFR in cancer. Elife. 2026 Apr 10; 13.
-
TAK1 is a key regulator of oncogenic signaling and differentiation blockade in rhabdomyosarcoma. Oncogene. 2026 May; 45(18):1714-1728.
-
Regulation of mitochondrial ROS by C15ORF48 in a basal cell subpopulation contributes to chemotherapy resistance in TNBC. Sci Adv. 2026 Apr 03; 12(14):eaec8684.